Article
Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2018
Falk Alexander T, Yazbeck Nathalie, Guibert Nicolas, Chamorey Emmanuel, Paquet Agnès, Ribeyre Lydia, Bence Coraline, Zahaf Katia, Leroy Sylvie, Marquette Charles-Hugo, Cohen Charlotte, Mograbi Baharia, Mazières Julien, Hofman Véronique, Brest Patrick, Hofman Paul, Ilié Marius
Abstract excerpt
OBJECTIVES: The effect of anti-PD-1/PD-L1 inhibitors on lung adenocarcinomas (LADCs) with KRAS mutations is debatable. We examined the association between specific mutant KRAS proteins and the immune infiltrates with the outcome of patients with LADCs. PATIENTS AND METHODS: In 219 LADCs harboring either wild-type (WT) or mutated KRAS gene, we quantified the density of several immune markers by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.